Is MYGN or QCLS more undervalued in 2026?

CirclFi compares Myriad Genetics, Inc. (MYGN) and Q/C Technologies, Inc. (QCLS) using 13 institutional-grade valuation models. MYGN has a Quality of Company score of 6.6/10 while QCLS scores 4.0/10.

Which is a better buy — MYGN or QCLS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do MYGN and QCLS valuations compare?

MYGN at $3.97 and QCLS at $4.37 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

MYGN vs QCLS Valuation Comparison 2026 — Intrinsic Value Analysis

MYGN

In Vitro & In Vivo Diagnostic Substances

Myriad Genetics, Inc.

Quality

6.6

out of 10

Value Trap

SAFE

Price

$3.97

Last close

Models

12/13

Active

QCLS

In Vitro & In Vivo Diagnostic Substances

Q/C Technologies, Inc.

Quality

4.0

out of 10

Value Trap

LOW

Price

$4.37

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	MYGN Fair Value	MYGN Upside	QCLS Fair Value	QCLS Upside
Bayesian DCF	Intrinsic	$0.08	-98.1%	$1.21	-72.3%
Earnings Power Value	Intrinsic	$16.62	+318.7%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$1.61	-59.4%	$0.11	-97.5%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for MYGN vs QCLS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MYGN vs QCLS — Which Stock Is More Undervalued?

MYGN scores higher with a 6.6/10 quality rating vs QCLS's 4.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Myriad Genetics, Inc. (MYGN) and Q/C Technologies, Inc. (QCLS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MYGN currently trades at $3.97 with a QOC of 6.6/10, while QCLS trades at $4.37 with a QOC of 4.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).